Renal Hemodynamic Effects of Serelaxin in Patients With Chronic Heart Failure: A Randomized, Placebo-Controlled Study

Adriaan A. Voors; Marion Dahlke; Sven Meyer; Janina Stepinska; Stephen S. Gottlieb; Andrew Jones; Yiming Zhang; Didier Laurent; Riemer H. J. A. Slart; Gerjan J. Navis

doi:10.1161/CIRCHEARTFAILURE.114.001536

Renal Hemodynamic Effects of Serelaxin in Patients With Chronic Heart Failure: A Randomized, Placebo-Controlled Study

Adriaan A. Voors^*
, Marion Dahlke
, Sven Meyer
, Janina Stepinska
, Stephen S. Gottlieb
, Andrew Jones
, Yiming Zhang
, Didier Laurent
, Riemer H. J. A. Slart
, Gerjan J. Navis

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

45 Citations (Scopus)

Abstract

Background-Serelaxin is a promising therapy for acute heart failure. The renal hemodynamic effects of serelaxin in patients with chronic heart failure are unknown.

Methods and Results-In this double-blind, randomized, placebo-controlled, multicenter study, patients with New York Heart Association Class II to III chronic heart failure, left ventricular ejection fraction

Conclusions-In patients with chronic heart failure, serelaxin increased renal plasma flow and reduced the increase in filtration fraction compared with placebo, but did not affect GFR. These results suggest beneficial renal hemodynamic effects in patients with chronic heart failure.

Original language	English
Pages (from-to)	994-1002
Number of pages	9
Journal	Circulation-Heart failure
Volume	7
Issue number	6
DOIs	https://doi.org/10.1161/CIRCHEARTFAILURE.114.001536
Publication status	Published - Nov-2014

Keywords

clinical trial
heart failure
hemodynamics
kidney
BLOOD-FLOW
RELAX-AHF
KIDNEY
IMPAIRMENT
INDEX

Access to Document

10.1161/CIRCHEARTFAILURE.114.001536

Handle.net

Persistent link

Embargoed Document

Renal Hemodynamic Effects of Serelaxin in Patients With Chronic Heart Failure
Final publisher's version, 451 KB
Request copy

Cite this

@article{d0cc83b63a4c466b8c8873714bbcd704,

title = "Renal Hemodynamic Effects of Serelaxin in Patients With Chronic Heart Failure: A Randomized, Placebo-Controlled Study",

abstract = "Background-Serelaxin is a promising therapy for acute heart failure. The renal hemodynamic effects of serelaxin in patients with chronic heart failure are unknown.Methods and Results-In this double-blind, randomized, placebo-controlled, multicenter study, patients with New York Heart Association Class II to III chronic heart failure, left ventricular ejection fractionConclusions-In patients with chronic heart failure, serelaxin increased renal plasma flow and reduced the increase in filtration fraction compared with placebo, but did not affect GFR. These results suggest beneficial renal hemodynamic effects in patients with chronic heart failure.",

keywords = "clinical trial, heart failure, hemodynamics, kidney, BLOOD-FLOW, RELAX-AHF, KIDNEY, IMPAIRMENT, INDEX",

author = "Voors, \{Adriaan A.\} and Marion Dahlke and Sven Meyer and Janina Stepinska and Gottlieb, \{Stephen S.\} and Andrew Jones and Yiming Zhang and Didier Laurent and Slart, \{Riemer H. J. A.\} and Navis, \{Gerjan J.\}",

year = "2014",

month = nov,

doi = "10.1161/CIRCHEARTFAILURE.114.001536",

language = "English",

volume = "7",

pages = "994--1002",

journal = "Circulation-Heart failure",

issn = "1941-3289",

publisher = "Lippincott Williams and Wilkins",

number = "6",

}

TY - JOUR

T1 - Renal Hemodynamic Effects of Serelaxin in Patients With Chronic Heart Failure

T2 - A Randomized, Placebo-Controlled Study

AU - Voors, Adriaan A.

AU - Dahlke, Marion

AU - Meyer, Sven

AU - Stepinska, Janina

AU - Gottlieb, Stephen S.

AU - Jones, Andrew

AU - Zhang, Yiming

AU - Laurent, Didier

AU - Slart, Riemer H. J. A.

AU - Navis, Gerjan J.

PY - 2014/11

Y1 - 2014/11

N2 - Background-Serelaxin is a promising therapy for acute heart failure. The renal hemodynamic effects of serelaxin in patients with chronic heart failure are unknown.Methods and Results-In this double-blind, randomized, placebo-controlled, multicenter study, patients with New York Heart Association Class II to III chronic heart failure, left ventricular ejection fractionConclusions-In patients with chronic heart failure, serelaxin increased renal plasma flow and reduced the increase in filtration fraction compared with placebo, but did not affect GFR. These results suggest beneficial renal hemodynamic effects in patients with chronic heart failure.

AB - Background-Serelaxin is a promising therapy for acute heart failure. The renal hemodynamic effects of serelaxin in patients with chronic heart failure are unknown.Methods and Results-In this double-blind, randomized, placebo-controlled, multicenter study, patients with New York Heart Association Class II to III chronic heart failure, left ventricular ejection fractionConclusions-In patients with chronic heart failure, serelaxin increased renal plasma flow and reduced the increase in filtration fraction compared with placebo, but did not affect GFR. These results suggest beneficial renal hemodynamic effects in patients with chronic heart failure.

KW - clinical trial

KW - heart failure

KW - hemodynamics

KW - kidney

KW - BLOOD-FLOW

KW - RELAX-AHF

KW - KIDNEY

KW - IMPAIRMENT

KW - INDEX

U2 - 10.1161/CIRCHEARTFAILURE.114.001536

DO - 10.1161/CIRCHEARTFAILURE.114.001536

M3 - Article

SN - 1941-3289

VL - 7

SP - 994

EP - 1002

JO - Circulation-Heart failure

JF - Circulation-Heart failure

IS - 6

ER -

Renal Hemodynamic Effects of Serelaxin in Patients With Chronic Heart Failure: A Randomized, Placebo-Controlled Study

Abstract

Keywords

Access to Document

Handle.net

Embargoed Document

Fingerprint

Cite this